Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

This grant invites bundled phase 1 and phase 1b/2a trials to streamline early-stage evaluation of novel pharmacological agents for Alzheimer’s disease and related dementias. It funds small-molecule or biologic interventions that target non-amyloid/non-tau mechanisms and aim to improve cognitive or neuropsychiatric symptoms across disease stages, with required safety and tolerability go/no-go milestones.

Amount: Not stated
Type: Grant

Key facts

Key facts for Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Amount	Not stated
Issuer	National Institutes of Health
Who can apply	Small businesses, companies, universities and 7 more
Sectors	HealthTech
Deadline	Closes 19 Nov 2026

Unlock application details

See all eligibility criteria, required documents and the official application link. Free account, no card.

Update history

Source: grants.gov ↗

Source checked yesterday

85 days agoagentImported from the official source

Opportunities with the same funding type or region
European Degree Exploratory Action		Closes 18 Feb 2027
Cooperative Agreement for affiliated Partner with Alaska Cooperative Ecosystem Studies Unit	up to $234,460	Closes 07 Dec 2026
Cooperative Agreement for affiliated Partner with Colorado Plateau Cooperative Ecosystem Studies Unit	up to $150,000	Closes 07 Dec 2026